COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey.
COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey.
复制标题
DOI：
10.1038/s41375-021-01302-5
复制
发表时间：
2021-10
期刊：
影响因子：
11.4
通讯作者：
Styczynski J
中科院分区：
文献类型：
--
作者：
Ljungman P;de la Camara R;Mikulska M;Tridello G;Aguado B;Zahrani MA;Apperley J;Berceanu A;Bofarull RM;Calbacho M;Ciceri F;Lopez-Corral L;Crippa C;Fox ML;Grassi A;Jimenez MJ;Demir SK;Kwon M;Llamas CV;Lorenzo JLL;Mielke S;Orchard K;Porras RP;Vallisa D;Xhaard A;Knelange NS;Cedillo A;Kröger N;Piñana JL;Styczynski J
本研究报告了382例接受异基因（n = 236）或自体（n = 146）造血细胞移植（HCT）的COVID-19患者，这些患者向欧洲血液和骨髓移植学会（EBMT）或西班牙造血干细胞移植组（GETH）报告。同种异体HCT患者的中位年龄为54.1岁（1.0-80.3），自体HCT患者的中位年龄为60.6岁（7.7-81.6）。从HCT到COVID-19的中位时间在同种异体中为15.8个月（0.2-292.7），在自体受体中为24.6个月（-0.9至350.3）。83.5%发生下呼吸道疾病，22.5%入住ICU。从诊断开始6周的总生存率在同种异体和自体受体中分别为77.9%和72.1%。儿童存活率为93.4%。在多变量分析中，年龄较大（p = 0.02），需要ICU（p < 0.0001）和中/高免疫缺陷指数（p = 0.04）增加了死亡风险，而更好的体力状态（p = 0.001）降低了死亡风险。其他因素如基础诊断、HCT、GVHD或持续免疫抑制的时间对总生存率无显著影响。我们得出结论，HCT患者发生LRTD的风险较高，需要入住ICU，并且在COVID-19中死亡率增加。
This study reports on 382 COVID-19 patients having undergone allogeneic (n = 236) or autologous (n = 146) hematopoietic cell transplantation (HCT) reported to the European Society for Blood and Marrow Transplantation (EBMT) or to the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH). The median age was 54.1 years (1.0–80.3) for allogeneic, and 60.6 years (7.7–81.6) for autologous HCT patients. The median time from HCT to COVID-19 was 15.8 months (0.2–292.7) in allogeneic and 24.6 months (−0.9 to 350.3) in autologous recipients. 83.5% developed lower respiratory tract disease and 22.5% were admitted to an ICU. Overall survival at 6 weeks from diagnosis was 77.9% and 72.1% in allogeneic and autologous recipients, respectively. Children had a survival of 93.4%. In multivariate analysis, older age (p = 0.02), need for ICU (p < 0.0001) and moderate/high immunodeficiency index (p = 0.04) increased the risk while better performance status (p = 0.001) decreased the risk for mortality. Other factors such as underlying diagnosis, time from HCT, GVHD, or ongoing immunosuppression did not significantly impact overall survival. We conclude that HCT patients are at high risk of developing LRTD, require admission to ICU, and have increased mortality in COVID-19.
登录
查看更多内容
影响因子：
11.4
作者：
Scarfo, Lydia;Chatzikonstantinou, Thomas;Ghia, Paolo
通讯作者：
Ghia, Paolo
影响因子：
36.4
作者：
Goetzinger, Florian;Santiago-Garcia, Begona;Tebruegge, Marc
通讯作者：
Tebruegge, Marc
DOI：
10.1093/cid/cis844
发表时间：
2013-01
期刊：
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
影响因子：
--
作者：
Hirsch HH;Martino R;Ward KN;Boeckh M;Einsele H;Ljungman P
通讯作者：
Ljungman P
造血细胞移植后的副氟藻病毒下呼吸道疾病：肺中的病毒检测可以预测结果。
DOI：
10.1093/cid/ciu134
发表时间：
2014-05
期刊：
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
影响因子：
--
作者：
Seo S;Xie H;Campbell AP;Kuypers JM;Leisenring WM;Englund JA;Boeckh M
通讯作者：
Boeckh M
DOI：
10.1093/infdis/jit832
发表时间：
2014-04-15
期刊：
The Journal of infectious diseases
影响因子：
--
作者：
Kim YJ;Guthrie KA;Waghmare A;Walsh EE;Falsey AR;Kuypers J;Cent A;Englund JA;Boeckh M
通讯作者：
Boeckh M